title: Deletion of thyrotropin receptor residue Asp403 in a hyperfunctioning thyroid nodule provides insight into the role of the ectodomain in ligand-induced receptor activation.
abstract: Somatic mutations of the TSH receptor (TSHR) gene are the main cause of autonomously functioning thyroid nodules. Except for mutations in ectodomain residue S281, all of the numerous reported activating mutations are in the TSHR membrane-spanning region. Here, we describe a patient with a toxic adenoma with a novel heterozygous somatic mutation caused by deletion of ectodomain residue Asp403 (Del-D403). Subsequent in vitro functional studies of the Del-D403 TSHR mutation demonstrated greatly increased ligand-independent constitutive activity, 8-fold above that of the wild-type TSHR. TSH stimulation had little further effect, indicating that the mutation produced near maximal activation of the receptor. In summary, we report only the second TSHR ectodomain activating mutation (and the first ectodomain deletion mutation) responsible for development of a thyroid toxic adenoma. Because Del-D403 causes near maximal activation, our finding provides novel insight into TSHR structure and function; residue D403 is more likely to be involved in the ligand-mediated activating pathway than in the ectodomain inverse agonist property.
authors: Center for Excellence in Thyroid Care, Kuma Hospital, Kobe, Japan. nishihara@kuma-h.or.jp
authors: E
authors: E
authors: Nishihara
authors: C-R
authors: CR
authors: Chen
authors: Y
authors: Y
authors: Mizutori-Sasai
authors: M
authors: M
authors: Ito
authors: S
authors: S
authors: Kubota
authors: N
authors: N
authors: Amino
authors: A
authors: A
authors: Miyauchi
authors: B
authors: B
authors: Rapoport
references: Mol Endocrinol. 2008 May;22(5):1171-82
references: 18218728
references: Mol Endocrinol. 2002 Apr;16(4):736-46
references: 11923470
references: Endocrinology. 2001 Jul;142(7):2760-7
references: 11415994
references: Endocr J. 2007 Dec;54(6):927-34
references: 18025759
references: Trends Biochem Sci. 2004 Mar;29(3):119-26
references: 15003269
references: Endocrinology. 2000 Sep;141(9):3514-7
references: 10965926
references: Endocr J. 2006 Dec;53(6):735-40
references: 16960398
references: J Clin Endocrinol Metab. 1997 Jan;82(1):306-8
references: 8989278
references: J Biol Chem. 2004 Dec 3;279(49):51590-600
references: 15345720
references: Endocr Rev. 2009 Apr;30(2):133-51
references: 19176466
references: J Biol Chem. 2006 Oct 20;281(42):31638-46
references: 16899458
references: Endocr Rev. 1998 Dec;19(6):673-716
references: 9861544
references: J Clin Invest. 1997 Sep 15;100(6):1634-9
references: 9294132
references: Thyroid. 2010 Nov;20(11):1307-14
references: 20929407
references: FEBS Lett. 1997 Jun 16;409(3):469-74
references: 9224711
references: J Clin Endocrinol Metab. 1998 May;83(5):1431-6
references: 9589634
references: Thyroid. 2003 Apr;13(4):341-3
references: 12804102
references: J Clin Endocrinol Metab. 1997 Nov;82(11):3885-91
references: 9360556
references: J Clin Endocrinol Metab. 1997 Aug;82(8):2695-701
references: 9253356
references: Endocr J. 2009;56(6):791-8
references: 19550078
references: J Mol Med (Berl). 2001;78(12):684-91
references: 11434721
references: J Endocrinol Invest. 1997 Jan;20(1):36-47
references: 9075071
references: Eur J Endocrinol. 2006 Oct;155(4):535-45
references: 16990652
references: Clin Endocrinol (Oxf). 2005 Aug;63(2):146-51
references: 16060907